Treatment With the Antisense Oligonucleotide Tofersen for SOD1 ALS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
N. Engl. J. Med 2022 Sep 22;387(12)1099-1110, TM Miller, ME Cudkowicz, A Genge, PJ Shaw, G Sobue, RC Bucelli, A Chiò, P Van Damme, AC Ludolph, JD Glass, JA Andrews, S Babu, M Benatar, CJ McDermott, T Cochrane, S Chary, S Chew, H Zhu, F Wu, I Nestorov, D Graham, P Sun, M McNeill, L Fanning, TA Ferguson, S FradetteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.